Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

A KLF6-driven transcriptional network links lipid homeostasis and tumour growth in renal carcinoma.

Syafruddin SE, Rodrigues P, Vojtasova E, Patel SA, Zaini MN, Burge J, Warren AY, Stewart GD, Eisen T, Bihary D, Samarajiwa SA, Vanharanta S.

Nat Commun. 2019 Mar 11;10(1):1152. doi: 10.1038/s41467-019-09116-x.

2.

Circulating Tumor Cells: Come Together, Right Now, Over Metastasis.

Rodrigues P, Vanharanta S.

Cancer Discov. 2019 Jan;9(1):22-24. doi: 10.1158/2159-8290.CD-18-1285.

3.

VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function.

Briston T, Stephen JM, Thomas LW, Esposito C, Chung YL, Syafruddin SE, Turmaine M, Maddalena LA, Greef B, Szabadkai G, Maxwell PH, Vanharanta S, Ashcroft M.

Front Oncol. 2018 Oct 4;8:388. doi: 10.3389/fonc.2018.00388. eCollection 2018.

4.

Endogenous HIF2A reporter systems for high-throughput functional screening.

Zaini MN, Patel SA, Syafruddin SE, Rodrigues P, Vanharanta S.

Sci Rep. 2018 Aug 13;8(1):12063. doi: 10.1038/s41598-018-30499-2.

5.

NF-κB-Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis.

Rodrigues P, Patel SA, Harewood L, Olan I, Vojtasova E, Syafruddin SE, Zaini MN, Richardson EK, Burge J, Warren AY, Stewart GD, Saeb-Parsy K, Samarajiwa SA, Vanharanta S.

Cancer Discov. 2018 Jul;8(7):850-865. doi: 10.1158/2159-8290.CD-17-1211. Epub 2018 Jun 6.

6.

Epigenetic determinants of metastasis.

Patel SA, Vanharanta S.

Mol Oncol. 2017 Jan;11(1):79-96. doi: 10.1016/j.molonc.2016.09.008. Epub 2016 Oct 8. Review.

7.

Tumor necrosis factor receptor 2-signaling in CD133-expressing cells in renal clear cell carcinoma.

Al-Lamki RS, Wang J, Yang J, Burrows N, Maxwell PH, Eisen T, Warren AY, Vanharanta S, Pacey S, Vandenabeele P, Pober JS, Bradley JR.

Oncotarget. 2016 Apr 26;7(17):24111-24. doi: 10.18632/oncotarget.8125.

8.

A hypoxic ticket to the bone metastatic niche.

Vanharanta S.

Breast Cancer Res. 2015 Sep 4;17:122. doi: 10.1186/s13058-015-0635-7. Review.

9.

Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations.

Jacob LS, Vanharanta S, Obenauf AC, Pirun M, Viale A, Socci ND, Massagué J.

Cancer Res. 2015 Sep 15;75(18):3713-9. doi: 10.1158/0008-5472.CAN-15-0562. Epub 2015 Jul 24.

10.

Therapy-induced tumour secretomes promote resistance and tumour progression.

Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, Lo RS, Massagué J.

Nature. 2015 Apr 16;520(7547):368-72. doi: 10.1038/nature14336. Epub 2015 Mar 25.

11.

Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer.

Vanharanta S, Marney CB, Shu W, Valiente M, Zou Y, Mele A, Darnell RB, Massagué J.

Elife. 2014 Jun 4;3. doi: 10.7554/eLife.02734.

12.

Origins of metastatic traits.

Vanharanta S, Massagué J.

Cancer Cell. 2013 Oct 14;24(4):410-21. doi: 10.1016/j.ccr.2013.09.007. Review.

13.

Hypoxia signaling--license to metastasize.

Vanharanta S, Massagué J.

Cancer Discov. 2013 Oct;3(10):1103-4. doi: 10.1158/2159-8290.CD-13-0481.

14.

Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer.

Vanharanta S, Shu W, Brenet F, Hakimi AA, Heguy A, Viale A, Reuter VE, Hsieh JJ, Scandura JM, Massagué J.

Nat Med. 2013 Jan;19(1):50-6. doi: 10.1038/nm.3029. Epub 2012 Dec 9.

15.

A CXCL1 paracrine network links cancer chemoresistance and metastasis.

Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE, Norton L, Brogi E, Massagué J.

Cell. 2012 Jul 6;150(1):165-78. doi: 10.1016/j.cell.2012.04.042.

16.

Field cancerization: something new under the sun.

Vanharanta S, Massagué J.

Cell. 2012 Jun 8;149(6):1179-81. doi: 10.1016/j.cell.2012.05.013.

17.

Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs.

Oskarsson T, Acharyya S, Zhang XH, Vanharanta S, Tavazoie SF, Morris PG, Downey RJ, Manova-Todorova K, Brogi E, Massagué J.

Nat Med. 2011 Jun 26;17(7):867-74. doi: 10.1038/nm.2379.

18.

Expression profiling in progressive stages of fumarate-hydratase deficiency: the contribution of metabolic changes to tumorigenesis.

Ashrafian H, O'Flaherty L, Adam J, Steeples V, Chung YL, East P, Vanharanta S, Lehtonen H, Nye E, Hatipoglu E, Miranda M, Howarth K, Shukla D, Troy H, Griffiths J, Spencer-Dene B, Yusuf M, Volpi E, Maxwell PH, Stamp G, Poulsom R, Pugh CW, Costa B, Bardella C, Di Renzo MF, Kotlikoff MI, Launonen V, Aaltonen L, El-Bahrawy M, Tomlinson I, Pollard PJ.

Cancer Res. 2010 Nov 15;70(22):9153-65. doi: 10.1158/0008-5472.CAN-10-1949. Epub 2010 Oct 26.

19.

The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

Tuupanen S, Turunen M, Lehtonen R, Hallikas O, Vanharanta S, Kivioja T, Björklund M, Wei G, Yan J, Niittymäki I, Mecklin JP, Järvinen H, Ristimäki A, Di-Bernardo M, East P, Carvajal-Carmona L, Houlston RS, Tomlinson I, Palin K, Ukkonen E, Karhu A, Taipale J, Aaltonen LA.

Nat Genet. 2009 Aug;41(8):885-90. doi: 10.1038/ng.406. Epub 2009 Jun 28.

PMID:
19561604
20.

Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer.

Koski TA, Lehtonen HJ, Jee KJ, Ninomiya S, Joosse SA, Vahteristo P, Kiuru M, Karhu A, Sammalkorpi H, Vanharanta S, Lehtonen R, Edgren H, Nederlof PM, Hietala M, Aittomäki K, Herva R, Knuutila S, Aaltonen LA, Launonen V.

Genes Chromosomes Cancer. 2009 Jul;48(7):544-51. doi: 10.1002/gcc.20663.

PMID:
19373782
21.

Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas.

Raimundo N, Vanharanta S, Aaltonen LA, Hovatta I, Suomalainen A.

Oncogene. 2009 Mar 5;28(9):1261-73. doi: 10.1038/onc.2008.472. Epub 2009 Jan 19.

PMID:
19151755
22.

Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype.

Petrova TV, Nykänen A, Norrmén C, Ivanov KI, Andersson LC, Haglund C, Puolakkainen P, Wempe F, von Melchner H, Gradwohl G, Vanharanta S, Aaltonen LA, Saharinen J, Gentile M, Clarke A, Taipale J, Oliver G, Alitalo K.

Cancer Cell. 2008 May;13(5):407-19. doi: 10.1016/j.ccr.2008.02.020.

23.

Stress-induced expression of a novel variant of human fumarate hydratase (FH).

Lehtonen HJ, Ylisaukko-Oja SK, Kiuru M, Karhu A, Lehtonen R, Vanharanta S, Jalanko A, Aaltonen LA, Launonen V.

Gene Expr. 2007;14(2):59-69.

24.

Allelic imbalance at rs6983267 suggests selection of the risk allele in somatic colorectal tumor evolution.

Tuupanen S, Niittymäki I, Nousiainen K, Vanharanta S, Mecklin JP, Nuorva K, Järvinen H, Hautaniemi S, Karhu A, Aaltonen LA.

Cancer Res. 2008 Jan 1;68(1):14-7. doi: 10.1158/0008-5472.CAN-07-5766.

25.

Definition of a minimal region of deletion of chromosome 7 in uterine leiomyomas by tiling-path microarray CGH and mutation analysis of known genes in this region.

Vanharanta S, Wortham NC, Langford C, El-Bahrawy M, van der Spuy Z, Sjöberg J, Lehtonen R, Karhu A, Tomlinson IP, Aaltonen LA.

Genes Chromosomes Cancer. 2007 May;46(5):451-8.

PMID:
17285575
26.

Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis.

Laiho P, Kokko A, Vanharanta S, Salovaara R, Sammalkorpi H, Järvinen H, Mecklin JP, Karttunen TJ, Tuppurainen K, Davalos V, Schwartz S Jr, Arango D, Mäkinen MJ, Aaltonen LA.

Oncogene. 2007 Jan 11;26(2):312-20. Epub 2006 Jul 3.

PMID:
16819509
27.

Distinct expression profile in fumarate-hydratase-deficient uterine fibroids.

Vanharanta S, Pollard PJ, Lehtonen HJ, Laiho P, Sjöberg J, Leminen A, Aittomäki K, Arola J, Kruhoffer M, Orntoft TF, Tomlinson IP, Kiuru M, Arango D, Aaltonen LA.

Hum Mol Genet. 2006 Jan 1;15(1):97-103. Epub 2005 Nov 30.

PMID:
16319128
28.

7q deletion mapping and expression profiling in uterine fibroids.

Vanharanta S, Wortham NC, Laiho P, Sjöberg J, Aittomäki K, Arola J, Tomlinson IP, Karhu A, Arango D, Aaltonen LA.

Oncogene. 2005 Sep 29;24(43):6545-54.

PMID:
15940248
29.

Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.

Lehtonen R, Kiuru M, Vanharanta S, Sjöberg J, Aaltonen LM, Aittomäki K, Arola J, Butzow R, Eng C, Husgafvel-Pursiainen K, Isola J, Järvinen H, Koivisto P, Mecklin JP, Peltomäki P, Salovaara R, Wasenius VM, Karhu A, Launonen V, Nupponen NN, Aaltonen LA.

Am J Pathol. 2004 Jan;164(1):17-22.

30.

Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Vanharanta S, Buchta M, McWhinney SR, Virta SK, Peçzkowska M, Morrison CD, Lehtonen R, Januszewicz A, Järvinen H, Juhola M, Mecklin JP, Pukkala E, Herva R, Kiuru M, Nupponen NN, Aaltonen LA, Neumann HP, Eng C.

Am J Hum Genet. 2004 Jan;74(1):153-9. Epub 2003 Dec 18.

31.

Reduced swelling-activated Cl(-) current densities in hypertrophied ventricular myocytes of rabbits with heart failure.

van Borren MM, Verkerk AO, Vanharanta SK, Baartscheer A, Coronel R, Ravesloot JH.

Cardiovasc Res. 2002 Mar;53(4):869-78.

PMID:
11922897

Supplemental Content

Loading ...
Support Center